In a randomized trial, adding an antiplatelet to anticoagulant therapy in patients with ischemic stroke, nonvalvular atrial fibrillation, and atherosclerosis provided no significant benefit. There was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback